Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
NCT03242759 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101
Last updated 2021-04-13
Summary
This is a non-interventional, multi-center study to collect data from patients with idiopathic pulmonary fibrosis (IPF) in clinical practice in Taiwan. The study will be carried out at 10 medical centers, the expert centers where IPF patients are mainly managed in Taiwan.
Conditions
Interventions
- DRUG
-
Drug
- DRUG
-
Drug
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-17
- Primary Completion
- 2020-02-18
- Completion
- 2020-02-18
Countries
- Taiwan
Study Locations
More Related Trials
-
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
NCT05065190 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
NCT00080223 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
NCT01504334 ·Status: UNKNOWN ·Phase: PHASE2
-
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
NCT04856111 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
NCT06241560 ·Status: RECRUITING ·Phase: PHASE2
-
Phase ll Study of HEC585 in Patients With IPF
NCT05060822 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pirfenidone in Adult Hospitalized Patients With COVID-19
NCT05713292 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
NCT05321082 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
NCT02999178 ·Status: COMPLETED ·Phase: PHASE3
-
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT07082842 ·Status: RECRUITING ·Phase: PHASE3
-
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
NCT04888715 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
NCT05383131 ·Status: COMPLETED ·Phase: PHASE1
-
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
NCT01979952 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT02598193 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
NCT02648048 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes
NCT04316780 ·Status: COMPLETED
-
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
NCT04161014 ·Status: UNKNOWN ·Phase: PHASE2
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT05938920 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
NCT07192939 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
NCT06764862 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
NCT03208933 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00662038 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Escalation Study of Artesunate Patients With IPF
NCT05988463 ·Status: RECRUITING ·Phase: PHASE1